# Endocrinology Sector

Canonical URL: https://biopharmsignal.com/sector/endocrinology

Endocrinology includes companies working on hormone-related disease, including diabetes, adrenal disorders, thyroid disease, and other metabolic or gland-driven conditions. It is a useful grouping for following companies exposed to chronic hormone-regulated disease categories.

Companies currently grouped under Endocrinology: 6

## Recent Sector News

- 2026-07-23 11:05 EST — VKTX — [Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors](https://biopharmsignal.com/news/VKTX/viking-therapeutics-appoints-dorothy-gemmell-to-board-of-directors-d154bd33) — Source: Viking Therapeutics
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f) — Source: Viking Therapeutics
- 2026-06-30 20:05 EST — CRNX — [Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026](https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-aug-4b8a9657) — Source: Crinetics Pharmaceuticals
- 2026-06-24 11:05 EST — VKTX — [Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-1-study-to-evaluate-novel-amyl-743d8a79) — Source: Viking Therapeutics
- 2026-06-14 20:30 EST — CRNX — [Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026](https://biopharmsignal.com/news/CRNX/crinetics-presents-full-results-from-phase-2-trial-of-atumelnant-in-congenital-a-c1c2be50) — Source: Crinetics Pharmaceuticals
- 2026-06-14 18:45 EST — CRNX — [Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control](https://biopharmsignal.com/news/CRNX/crinetics-presents-long-term-data-at-endo-2026-confirming-palsonify-paltusotine--eaa37cc2) — Source: Crinetics Pharmaceuticals
- 2026-06-11 11:05 EST — VKTX — [Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-appointment-of-hubert-c-chen-m-d-as-chief-medical--ca51f016) — Source: Viking Therapeutics
- 2026-06-03 12:30 EST — NBIX — [Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-new-two-year-crenessityr-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026) — Source: Neurocrine Biosciences
- 2026-06-02 20:05 EST — CRNX — [Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities](https://biopharmsignal.com/news/CRNX/crinetics-and-leading-patient-groups-launch-everyday-advocacy-initiative-to-empo-3a497246) — Source: Crinetics Pharmaceuticals
- 2026-06-02 08:55 EST — CRNX — [Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations](https://biopharmsignal.com/news/CRNX/crinetics-paradigm-shifting-portfolio-and-pipeline-on-display-at-endo-2026-with--b53db9a2) — Source: Crinetics Pharmaceuticals
- 2026-05-29 20:33 EST — CORT — [Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure](https://biopharmsignal.com/news/CORT/corcept-presents-new-data-at-asco-2026-lifyorlitm-overall-survival-across-all-subgroups-of-patients-with-platinum-resistant-ovarian-cancer-including-those-with-recent-taxane-exposure) — Source: Corcept
- 2026-05-27 12:00 EST — CORT — [Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome](https://biopharmsignal.com/news/CORT/corcept-to-resubmit-its-new-drug-application-for-relacorilant-as-a-treatment-for-patients-with-cushing-s-syndrome) — Source: Corcept
- 2026-05-26 20:01 EST — NBIX — [Neurocrine Biosciences to Present at Upcoming Investor Conferences in June](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-june) — Source: Neurocrine Biosciences
- 2026-05-22 20:05 EST — CRNX — [Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026](https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-jefferies-global-healthcare-conferen-eacfb4e3) — Source: Crinetics Pharmaceuticals
- 2026-05-21 11:05 EST — VKTX — [Viking Therapeutics to Participate at Upcoming Investor Conferences](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-239640de) — Source: Viking Therapeutics
- 2026-05-18 20:05 EST — NBIX — [Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-real-world-data-highlighting-functional-impact-of-mild-tardive-dyskinesia-severity-and-improvement-with-ingrezzar-valbenazine-capsules) — Source: Neurocrine Biosciences
- 2026-05-18 12:46 EST — NBIX — [Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-completes-acquisition-of-soleno-therapeutics) — Source: Neurocrine Biosciences
- 2026-05-12 11:05 EST — VKTX — [Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026) — Source: Viking Therapeutics
- 2026-05-07 20:05 EST — CRNX — [Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provi-b5dbce2c) — Source: Crinetics Pharmaceuticals
- 2026-05-06 12:30 EST — NBIX — [Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-publication-of-expert-recommendations-for-glucocorticoid-dose-reduction-after-initiating-crenessityr-crinecerfont-for-the-treatment-of-classic-congenital-adrenal-hyperplasia) — Source: Neurocrine Biosciences

## Companies

- [AMPH](https://biopharmsignal.com/company/AMPH) — Amphastar Pharmaceuticals, Inc.
- [CORT](https://biopharmsignal.com/company/CORT) — Corcept
- [CRNX](https://biopharmsignal.com/company/CRNX) — Crinetics Pharmaceuticals
- [NBIX](https://biopharmsignal.com/company/NBIX) — Neurocrine Biosciences
- [SPRB](https://biopharmsignal.com/company/SPRB) — Spruce Biosciences
- [VKTX](https://biopharmsignal.com/company/VKTX) — Viking Therapeutics